Alembic Pharma Q4 Results: Net profit rises 29% YoY even as margin declines

Alembic Pharmaceuticals reported a strong rise in consolidated net profit for the fourth quarter ended March 31, 2026, even as the company witnessed pressure on operating margins during the quarter.

The company’s consolidated net profit rose 29.2% year-on-year to ₹202.70 crore in Q4 FY26, compared to ₹156.89 crore reported in the corresponding quarter last year.

Revenue from operations during the quarter increased 4.4% YoY to ₹1,847.72 crore, as against ₹1,769.64 crore in Q4 FY25.

EBITDA for the quarter stood at ₹227.93 crore, down 16.2% from ₹271.93 crore in the year-ago period. EBITDA margin contracted to 12.3% in Q4 FY26 from 15.4% in Q4 FY25.

Total income for the quarter came in at ₹1,873.22 crore, compared to ₹1,783.83 crore in the corresponding quarter last year.

Employee benefit expenses rose to ₹438.91 crore during the quarter from ₹393.59 crore a year ago, while other expenses stood at ₹648.74 crore compared to ₹573.51 crore in Q4 FY25. Depreciation and amortisation expenses increased to ₹88.59 crore from ₹68.99 crore in the year-ago quarter.

Profit before tax stood at ₹118.62 crore for the quarter, compared to ₹191.95 crore reported in the corresponding period last year. However, the company benefited from a deferred tax gain of ₹114.21 crore during the quarter.

Total comprehensive income attributable to owners of the company stood at ₹214.54 crore in Q4 FY26, compared to ₹162.42 crore in the year-ago period.

Basic and diluted earnings per share for the quarter came in at ₹10.31, compared to ₹7.98 in Q4 FY25.

The company’s board has also recommended a dividend of ₹12 per equity share having a face value of ₹2 each for FY26, translating into a 600% dividend payout. The proposed dividend is subject to shareholders’ approval at the ensuing Annual General Meeting of the company.